Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies
Ananta Swargiary
doi:10.21203/rs.3.rs-73308/v1
Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, RNA-dependent RNA polymerase, 3-chymotrypsin-and papainlike proteases of SARS-CoV2. Methods: The 3D structure of ivermectin along with known antiviral drug lopinavir, simeprevir and four nucleotides ATP, GTP, CTP, and UTP were
Ethics approval: NA Consent to participate: NA Consent for publication: Author gives the consent to publish the manuscript
References
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld et al., Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase, J Biomol Struct Dyn. Doi,
doi:10.1126/science.1085658Benvenuto, Giovanetti, Ciccozzi, Spoto, Angeletti et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res,
doi:10.1002/jmv.25688Canga, Prieto, Liebana, Martinez, Vega et al., The Pharmacokinetics and Interactions of Ivermectin in Humans -A Mini-review, AAPS J,
doi:10.1208/s12248-007-9000-9Chen, Yiu, Wong, Prediction of the SARSCoV-2 (2019-nCoV) 3C-like protease (3CL (pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates, F1000Research,
doi:10.12688/f1000research.22457.1Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res,
doi:.org/10.1016/j.antiviral.2018.09.010Patrì, Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, J Am Acad Dermatol,
doi:10.1016/j.jaad.2020.04.017Sharun, Dhama, Patel, Pathak, Tiwari et al., Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob,
doi:10.1186/s12941-020-00368-wTouret, Gilles, Barral, Nougairede, Helden et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep,
doi:10.1038/s41598-020-70143-6Trott, Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, e cient optimization and multithreading, J Comput Chem,
doi:10.1002/jcc.21334Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Xu, Liu, Weiss, Sg, Ding, Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design, Nucleic Acids Res,
doi:10.1093/nar/gkg916Yin, Mao, Luan, Shen, Shen et al., Structural basis for inhibition of the RNAdependent RNA polymerase from SARS-CoV-2 by remdesivir, Science,
doi:10.1126/science.abc1560Zhou, Fang, Yang, Xu, Lv et al., Identi cation of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach, The FASEB Journal,
doi:10.1096/fj.201901624RRDOI record:
{
"DOI": "10.21203/rs.3.rs-73308/v1",
"URL": "http://dx.doi.org/10.21203/rs.3.rs-73308/v1",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, RNA-dependent RNA polymerase, 3-chymotrypsin- and papain-like proteases of SARS-CoV2. Methods: The 3D structure of ivermectin along with known antiviral drug lopinavir, simeprevir and four nucleotides ATP, GTP, CTP, and UTP were downloaded from PubChem database. Crystal structures of proteins were downloaded from PDB database. PDB files were converted into pdbqt file using AutoDock tools. After proper processing and grid formation, docking was carried out in AutoDock vina. Furthermore, the co-crystallized RNA and its binding interactions with RdRp were studied using various visualization tools including Discovery studio.Results: Docking study showed that ivermectin is the best binding drug compared to lopinavir and simeprevir. The best binding interaction was found to be -9.7kcal/mol with RdRp suggesting potential inhibitor of the protein. Twenty-one amino acid residues of RdRp were found to interact with ivermectin including the catalytic residue Asp760. Furthermore, RNA-RdRp complex revealed that the catalytic active residues Ser759 and Asp760 of RdRp formed strong interactions with RNA chain. Binding of ivermectin in the active site of RdRp make clash with the nucleotides of RNA chain suggesting the possible inhibition of replication.Conclusions: The present study suggests ivermectin as a potential inhibitor of RdRp which may be crucial to combat the SARS-CoV2.</jats:p>",
"accepted": {
"date-parts": [
[
2020,
9,
7
]
]
},
"author": [
{
"ORCID": "http://orcid.org/0000-0001-9594-3666",
"affiliation": [
{
"name": "Department of Zoology, Bodoland University"
}
],
"authenticated-orcid": false,
"family": "Swargiary",
"given": "Ananta",
"sequence": "first"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
9,
9
]
],
"date-time": "2020-09-09T23:32:50Z",
"timestamp": 1599694370000
},
"deposited": {
"date-parts": [
[
2021,
3,
17
]
],
"date-time": "2021-03-17T18:46:53Z",
"timestamp": 1616006813000
},
"group-title": "In Review",
"indexed": {
"date-parts": [
[
2024,
4,
13
]
],
"date-time": "2024-04-13T15:30:20Z",
"timestamp": 1713022220401
},
"institution": [
{
"name": "Research Square"
}
],
"is-referenced-by-count": 7,
"issued": {
"date-parts": [
[
2020,
9,
9
]
]
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
9,
9
]
],
"date-time": "2020-09-09T00:00:00Z",
"timestamp": 1599609600000
}
}
],
"link": [
{
"URL": "https://www.researchsquare.com/article/rs-73308/v1",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.researchsquare.com/article/rs-73308/v1.html",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "8761",
"original-title": [],
"posted": {
"date-parts": [
[
2020,
9,
9
]
]
},
"prefix": "10.21203",
"published": {
"date-parts": [
[
2020,
9,
9
]
]
},
"publisher": "Research Square Platform LLC",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.researchsquare.com/article/rs-73308/v1"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies",
"type": "posted-content"
}
